Imricor Medical Systems and Philips have launched a combined interventional MR lab solution integrating Philips’ 1.5T BlueSeal MRI with Imricor’s MR-compatible systems, targeting cardiac electrophysiology and setting a new standard for MR-guided interventions.
- Commercial launch of integrated iMR lab solution
- Combines Philips’ 1.5T BlueSeal MRI with Imricor’s MR systems
- Focus on MR-guided cardiac electrophysiology procedures
- Available immediately in CE-marked markets, selected US configurations
- Platform designed for scalable expansion into other iMR procedures
Philips and Imricor Deliver First Combined iMR Lab Solution
Imricor Medical Systems (ASX:IMR) and Philips (NYSE: PHG) have taken a significant step forward in MR-guided cardiac care with the commercial launch of a combined interventional magnetic resonance (iMR) lab solution. This new offering integrates Philips’ 1.5 Tesla BlueSeal helium-free MR platform with Imricor’s NorthStar® Mapping System, Advantage-MR® EP Recorder/Stimulator, and a suite of MR-compatible single-use catheters and tools. The solution is designed to enable real-time MR-guided cardiac interventions, particularly electrophysiology procedures, within a purpose-built interventional environment.
Advancing MR-Guided Cardiac Interventions Beyond Diagnostics
Unlike traditional approaches that retrofit diagnostic MRI suites for interventions, this collaboration brings MR imaging directly into the procedure room. Steve Wedan, Imricor’s CEO, emphasised the innovation: "Pairing Philips’ world-class 1.5T MR platform with Imricor’s exclusive portfolio creates the world’s first state-of-the-art high-performance iMR lab solution." The partnership aims to shift cardiac MRI from purely diagnostic use into active therapeutic guidance, enhancing precision and safety in cardiac electrophysiology.
Immediate Availability and Regulatory Landscape
The initial configuration is commercially available now in CE-marked markets across Europe and other regions, with selected configurations also available in the United States. Further US configurations are anticipated pending regulatory approvals. The launch follows Philips’ recent Third Party Declaration of Compatibility with Imricor’s devices, a key regulatory milestone that underpins this commercial offering. This positions Imricor’s technology alongside one of the world’s leading MR imaging providers, broadening its route to market and clinical adoption.
A Platform for Future iMR Procedures
Designed as a scalable commercial platform, the iMR lab solution lays the groundwork for expanding MR-guided interventions beyond cardiac electrophysiology. Philips’ Business Leader for Magnetic Resonance, Ioannis Panagiotelis, highlighted the strategic vision: "Cardiac electrophysiology is just the beginning. This platform can expand into additional clinical areas while helping clinicians deliver the best possible care." The collaboration between Philips and Imricor, which dates back to 2012, has evolved from joint technology development to this commercial milestone, signalling growing maturity and market readiness of iMR technology.
Imricor’s Position in the Growing MR-Guided Intervention Market
Imricor is a pioneer in MR-compatible interventional products, with its capital equipment and consumables approved in multiple global markets including the EU, Saudi Arabia, and New Zealand, and select US clearances for NorthStar and Vision-MR catheters. The company’s US commercial expansion has gained traction recently, including with leading pediatric hospitals, supported by FDA clearances that enable radiation-free cardiac procedures across age groups. This launch with Philips enhances Imricor’s commercial footprint and technological leadership, potentially accelerating adoption in a market seeking safer, more effective cardiac interventions.
Bottom Line?
This commercial launch marks a pivotal step for Imricor and Philips, but the pace of US market expansion will hinge on forthcoming regulatory clearances and clinical uptake.
Questions in the middle?
- How quickly will the US regulatory environment approve additional iMR lab configurations?
- What clinical evidence will drive broader adoption of MR-guided cardiac interventions beyond electrophysiology?
- Can this combined platform effectively scale into other interventional areas to justify its commercial potential?